Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2013

View Archived Issues

Servier partners with SIgN for immunomodulatory drugs

Sanofi's Complavin combination tablets approved in Japan

Stanford University presents 64Cu-NOTA-B-Fab, an immuno-PET tracer companion diagnostic

Proximagen begins phase II PRX-167700 study of knee osteoarthritis

Phase III study of BioMarin's BMN-673 in metastatic breast cancer commences

Bioheart forms license agreement with Invitrx

Cornerstone Pharmaceuticals begins phase II CPI-613 trial in MDS

Torrent Pharmaceuticals presents first clinical data for TRC-150094

Gemigliptin is safe and efficient as a long-term treatment added to ongoing metformin

DatSCAN intravenous injection approved in Japan

Ablynx and Merck Serono expand nanobodies partnership

Program to evaluate LUM-001 in Alagille syndrome, FDA grants LUM-001 orphan drug designations

Merck KGaA to renew testing of lung cancer vaccine

Tetra Discovery receives phase II SBIR grant to develop new depression drug

Bio-Matrix Scientific provides update on dCellVax for breast cancer

Novo Nordisk files application to expand approval of liraglutide in Japan

Mologen submits MGN-1703 IND application with FDA

Simeprevir obtains first approval in Japan

CSL Behring gains Japanese approval for Hizentra

Alnylam Pharmaceuticals reports interim results from phase I ALN-TTRsc trial

Experimental LTC4S gene overexpression replicates aspirin-induced asthma

TNF-alpha production inhibitors reported by PuraPharm and Versitech

Lupin discovers nAChR alpha7 modulators

Cadila Healthcare divulges discovery of PCSK9 inhibitors

Merck & Co. prepares and tests novel PAR-1 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...